Across TCGA pan-cancer cohorts, ZBTB10 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZBTB10 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ZBTB10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZBTB10 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, LSCC, and CCRCC are the cancer types where ZBTB10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.287	0.702	.007	8	view →
LSCC	DFS	Median	III,IV	1.000	0.616	.017	6	view →
CCRCC	DFS	Quartile	II,III,IV	0.448	0.840	.019	4	view →
HNSC	OS	Quartile	All	0.380	1.000	.027	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZBTB10 tumor-vs-normal RNA expression · all ZBTB10 data types